Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
26 hedge funds and large institutions have $4.26M invested in Vyant Bio, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
16% more capital invested
Capital invested by funds: $3.66M → $4.26M (+$592K)
13% more funds holding
Funds holding: 23 → 26 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$286K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$279K |
| 3 |
Renaissance Technologies
New York
|
+$86.7K |
| 4 |
VF
Virtu Financial
New York
|
+$44.8K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$32.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$767K |
| 2 |
FCM
Fairbanks Capital Management
Rancho Santa Fe,
California
|
-$9.92K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$9K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$5.48K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4.59K |
VYNT Hedge Fund Activity: Q3 2018 in Review
26 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q3 2018, worth a combined $4.26M — up 16% from $3.66M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new VYNT positions and 2 closed out — a net gain of 3 holders — while 7 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $286K. The largest seller was Stonepine Capital Management, cutting an estimated $767K.
- 26 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q3 2018, up from 23 in Q2 2018.
- Funds reported $4.26M of Vyant Bio, Inc. Common Stock stock for Q3 2018, up 16% quarter-over-quarter.
- 5 funds opened new Vyant Bio, Inc. Common Stock positions in Q3 2018 and 2 closed out, a net change of +3 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q3 2018 was Vanguard Group, an estimated $286K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q3 2018 was Stonepine Capital Management, an estimated $767K sold.
Based on aggregated 13F filings for Q3 2018.